Ascendis Pharma A/S (ASND) Set to Announce Quarterly Earnings on Thursday

Ascendis Pharma A/S (NASDAQ:ASND) is set to release its earnings data after the market closes on Thursday, November 14th. Analysts expect Ascendis Pharma A/S to post earnings of ($1.54) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. On average, analysts expect Ascendis Pharma A/S to post $-7 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $127.67 on Wednesday. The stock has a 50 day moving average price of $131.91 and a 200-day moving average price of $132.90. Ascendis Pharma A/S has a one year low of $86.54 and a one year high of $161.00. The company has a market capitalization of $7.74 billion, a P/E ratio of -13.71 and a beta of 0.66.

Wall Street Analyst Weigh In

Several equities analysts have commented on ASND shares. Oppenheimer reiterated an “outperform” rating and set a $190.00 price objective (up previously from $180.00) on shares of Ascendis Pharma A/S in a research report on Tuesday, September 17th. StockNews.com lowered Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Tuesday. Jefferies Financial Group boosted their price objective on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research note on Tuesday, August 13th. Bank of America raised their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Finally, Wells Fargo & Company boosted their target price on Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and an average target price of $195.92.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.